Page last updated: 2024-11-04

palmitoylcarnitine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Palmitoylcarnitine: A long-chain fatty acid ester of carnitine which facilitates the transfer of long-chain fatty acids from cytoplasm into mitochondria during the oxidation of fatty acids. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

O-palmitoyl-L-carnitine : An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11953816
CHEMBL ID3392050
CHEBI ID17490
SCHEMBL ID116634
MeSH IDM0015783

Synonyms (57)

Synonym
palmitoyl d-carnitine
(+)-palmitoylcarnitine
d-palmitylcarnitine
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, palmitate, l-
palmityl-l-carnitine
palmitoyl-l-(-)-carnitin [german]
(3r)-3-hexadecanoyloxy-4-(trimethylammonio)butanoate
CHEBI:17490 ,
hexadecanoylcarnitine
hexadecenoyl carnitine
(3r)-3-(hexadecanoyloxy)-4-(trimethylazaniumyl)butanoate
l-carnitine palmitoyl ester
o-hexadecanoyl-(r)-carnitine
palmitoyl-l-carnitine
hexadecanoyl-l-carnitine
(3r)-3-palmitoyloxy-4-(trimethylammonio)butanoate
palmitoylcarnitine
LMFA07070004
o-hexadecanoyl-r-carnitine
o-palmitoyl-l-carnitine
2364-67-2
C02990
o-hexadecanoyl-l-carnitine
palmitylcarnitine
l-palmitoylcarnitine
palmitoyl carnitine
1g38o5k038 ,
palmitoyl-l-(-)-carnitin
unii-1g38o5k038
palmitoyl carnitine, (-)-
SCHEMBL116634
l(-)-palmitylcarnitine
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-((1-oxohexadecyl)oxy)-, inner salt, (2r)-
palmitic acid, ester with (3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt, l-
palmitoyl-(-)-carnitine
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-((1-oxohexadecyl)oxy)-, inner salt, (r)-
XOMRRQXKHMYMOC-OAQYLSRUSA-N
CHEMBL3392050 ,
palmitoyl-l-carnitine, >=97.0% (tlc)
car(16:0)
(3s)-3-palmitoyloxy-4-(trimethylammonio)butanoic acid
l-palmitoyl-l-carnitine
(3s)-3-hexadecanoyloxy-4-(trimethylammonio)butanoic acid
3-carboxy-n,n,n-trimethyl-2-[(1-oxohexadecyl)oxy]-1-propanaminium
c16 carnitine, palmitoyl l-carnitine, powder
(3r)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate
Q27102424
(-)-palmitoyl carnitine
DTXSID101019091
HY-113147
CS-0062278
bdbm50537024
AS-57239
AKOS037645114
l-palmitoyl carnitine
XP165791
PD101999

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Cephaloglycin (Cgl) and cephaloridine (Cld) are acutely toxic to the proximal renal tubule, in part because of their cellular uptake by a contraluminal anionic secretory carrier and in part through their intracellular attack on the mitochondrial transport and oxidation of tricarboxylic acid (TCA) cycle anionic substrates."( Toxicity of cephalosporins to fatty acid metabolism in rabbit renal cortical mitochondria.
Hsu, CY; Tune, BM, 1995
)
0.29
" Cld has little or no in vivo toxicity to mitochondrial butyrate metabolism, whereas in vivo Cgl is as toxic as Cld to respiration with PCarn."( Toxicity of cephalosporins to fatty acid metabolism in rabbit renal cortical mitochondria.
Hsu, CY; Tune, BM, 1995
)
0.29
", no separation between effective and toxic concentration)."( Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers.
LeCluyse, EL; Liu, DZ; Thakker, DR, 1999
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, the effects of the anthracycline antibiotics on skin tumor promotion were evaluated in combination with the Ca2+ antagonist verapamil (VRP) and the protein kinase C (PKC) inhibitor palmitoylcarnitine (PC), compounds known to circumvent drug resistance."( Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine.
Perchellet, JP; Satyamoorthy, K, 1990
)
0.28

Bioavailability

ExcerptReferenceRelevance
"The conditions under which the absorption enhancer palmitoyl L-carnitine chloride (PCC) improved the bioavailability of the poorly absorbed antibiotic cefoxitin throughout the rat intestine has been studied."( Enhanced bioavailability of cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions.
Cammack, L; Fix, JA; LeCluyse, EL; Sutton, SC, 1992
)
0.28
" The increase in peak height was calculated relative to nasal administration of hGH alone without any enhancers and the relative bioavailability was calculated with reference to subcutaneous injection data."( Nasal absorption enhancers for biosynthetic human growth hormone in rats.
Critchley, H; Davis, SS; Farraj, NF; Fisher, AN; Illum, L; Johansen, BR; O'Hagan, DT, 1990
)
0.28
"Acylcarnitines were tested as potential absorption-enhancing agents for drugs that are poorly absorbed from the gastrointestinal tract."( Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract.
Alexander, J; Engle, K; Fix, JA; Gardner, CR; Leppert, PS; Porter, PA; Selk, SJ, 1986
)
0.27
" Regardless of the mechanism, palmitoyl carnitine's ability to selectively increase the transmeningeal flux of hydrophilic compounds in vitro offers the possibility of improving the spinal bioavailability of this group of epidurally administered drugs in vivo."( Palmitoyl carnitine increases the transmeningeal flux of hydrophilic but not hydrophobic compounds in vitro.
Bernards, CM; Kern, C, 1996
)
0.29
"Following epidural administration, cerebrospinal fluid bioavailability of local anesthetics is low, one major limiting factor being diffusion across the arachnoid mater barrier."( Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers.
Brandhonneur, N; Chevanne, F; Deniau, AL; Dollo, G; Estèbe, JP; Le Corre, P; Legrand, A; Ratajczak-Enselme, M, 2011
)
0.37
"We examined the effect of acylcarnitines on the in situ bioavailability of lucifer yellow (LY) from the loops of small and large intestines of rats."( Increases in bioavailability of poorly absorbed drug by acylcarnitine.
Doi, N; Hayashi, M; Kimura, A; Tomita, M, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The data also demonstrated effectiveness with aqueous and solid dosage forms (Witepsol H-15 suppositories)."( Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract.
Alexander, J; Engle, K; Fix, JA; Gardner, CR; Leppert, PS; Porter, PA; Selk, SJ, 1986
)
0.27
" A time course and the dose-response curves of ODC induction paralleled that of ODC mRNA induction by TPA in MEC."( Involvement of protein kinase C activation in ornithine decarboxylase gene expression in primary culture of newborn mouse epidermal cells and in skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Erickson, D; Pong, RC; Verma, AK, 1986
)
0.27
" The drug did, however, induce hepatic lipid accumulation in mature rats and in young rats dosed concomitantly with phenobarbital."( The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.
Granneman, GR; Kesterson, JW; Machinist, JM,
)
0.13
"5 to 2 microM, these FFA metabolites stimulated ATP synthesis; however, above 5 microM, there was a dose-response inhibition of ATP synthesis."( Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance.
Abdul-Ghani, MA; Balas, B; Chang, Z; Chavez, AO; DeFronzo, RA; Folli, F; Jani, R; Liu, Y; Molina-Carrion, M; Monroy, A; Muller, FL; Tripathy, D; Van Remmen, H; Zuo, P, 2008
)
0.35
" Huperzine A's permeability characteristics pave the way to the development of its oral extended release dosage form."( Transepithelial transport of a natural cholinesterase inhibitor, huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism.
Burshtein, G; Friedman, M; Greenberg, S; Hoffman, A, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
O-palmitoylcarnitineAn O-acylcarnitine having palmitoyl (hexadecanoyl) as the acyl substituent.
saturated fatty acyl-L-carnitineAn O-acylcarnitine in which the R is a saturated fatty acyl chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (18)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Carnitine metabolism1013
Signaling Pathways1269117
Signaling by Nuclear Receptors15246
Signaling by Retinoic Acid2431
Fatty Acid Metabolism1441
Ethylmalonic Encephalopathy1441
Glutaric Aciduria Type I1441
Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency)1441
Carnitine Palmitoyl Transferase Deficiency I1441
Long Chain Acyl-CoA Dehydrogenase Deficiency (LCAD)1441
Very-Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD)1441
Carnitine Palmitoyl Transferase Deficiency II1441
Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)1441
Trifunctional Protein Deficiency1441
mitochondrial L-carnitine shuttle04
mitochondrial L-carnitine shuttle88
Metabolism overview078

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent glycine transporter 2Homo sapiens (human)IC50 (µMol)0.60000.026012.7472128.0000AID1638510
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
neurotransmitter transportSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
chemical synaptic transmissionSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
synaptic transmission, glycinergicSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
glycine import across plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
glycine:sodium symporter activitySodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
metal ion bindingSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endosomeSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
dense core granuleSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
glycinergic synapseSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
plasma membraneSodium- and chloride-dependent glycine transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1638510Reversible non-competitive inhibition of human GlyT2a expressed in Xenopus laevis oocytes by two-electrode voltage clamp electrophysiology2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (395)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990148 (37.47)18.7374
1990's117 (29.62)18.2507
2000's62 (15.70)29.6817
2010's57 (14.43)24.3611
2020's11 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.24%)5.53%
Reviews7 (1.70%)6.00%
Case Studies6 (1.46%)4.05%
Observational0 (0.00%)0.25%
Other398 (96.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]